A bipartisan group of senators is exploring whether price hikes could be used as a trigger to include a drug on FDA's drug shortage list, which could in turn spur competition to accelerate approval of competing products, a congressional aide told Inside Health Policy . The lawmakers, prompted by Mylan Pharmaceuticals' controversial price increase for EpiPens, wrote to FDA Wednesday (Aug. 24) asking what situations would warrant changes to the typical FDA approval timeline, such as drug shortages, and the...